32 results about "ENDOGLYCAN" patented technology

Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions comprising: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CD1d on a dendritic cell, such as an α-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions comprising the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM197.

Disclosed are hybrid genes of glucanase and dextransucrase, recombinant vectors comprising said hybrid genes, microorganisms which are transformed with said recombinant vectors, hybrid enzymes which are expressed from said hybrid genes, and processes for preparing isomalto-oligosaccharides or dextran using said microorganisms or enzymes. Expensive isomalto-oligosaccharides and low molecular weight dextran for clinical use can be produced simply and effectively from cheap substrate-sucrose, using a single bacterial strain or enzyme.

The invention discloses a pollen natto tablet, which comprises the following components in parts by weight: 4-5 parts of pollen, 3-4 parts of natto, 1-2 parts of anka and 1-2 parts of oligosaccharide. The pollen uses bee pollen as a raw material. The method for preparing the pollen comprises the following steps: firstly sprying the raw material bee pollen with 50-100PPM ClO2 aqueous solution; sterilizing for 30 minutes in a closed manner; adjusting humidity to 25%; then inoculating ferments to ferment at the temperature of 30-37 DEG C for 12 hours; and verifying acidity, cryodrying to obtain the pollen when the PH value is 4.5. The pollen natto tablet of the invention generates secondary products such as multiple enzymes, lactic acid, vitamin and the like after the raw material is fermented with beneficial bacterium, and combines the health care functions of the raw material and beneficial microorganisms, therefore the pollen natto tablet can supply human body with balanced nutrition, adjust human body endocrine metabolism, promote recovery of certain diseases, and improve human sub-health state.

Methods and kits for detecting cancer and monitoring cancer progression are described. The method involves analyzing a sample containing nucleic acids or proteins from a patient for decreased expression of endoglycan and / or increased expression of podocalyxin.

Disclosed are novel methods of treatment for retinal diseases and conditions including age-related macular degeneration, genetic-based retinal degenerations and retinal detachment. A novel glycan binding protein thought to be a cell surface receptor has been discovered in the retina. The retinal glycan binding receptor is shown to play an important role in promoting assembly of outer segment (OS) membranes by the photoreceptor cells of the eye, a process that is essential for vision. Based on the finding that certain sugars can bind with very high affinity to the retinal glycan receptor and stimulate its function, the invention provides novel therapeutic agents for treatment of retinal diseases that are multivalent N-linked glycans. Preferred pharmaceutical compositions in accordance with the present invention comprise active agents having the general formula: (Gal-GlcNAc)n-Man3-GlcNAc2, where n is 1-4. Particularly preferred multivalent glycans are galactosylated, biantennary (NA2), and asialo, galactosylated, triantennary (NA3) oligosaccharides.

The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor.

Described is a matrix to identify mother's milk missing fucosyltransferase-2 (FUT2) dependent glycans which comprise a line of a glycan binding protein such as a lectin or antibody suitable to bind 2'fucosyl-glycans and a line of a positive control to bind a mother's milk protein. For instance, this matrix is porous and allows for transport by capillary force of compounds of mother's milk such asglycoproteins. Especially, the glycan binding protein is the plant lectin from Ulex europaeus. A diagnostic kit comprising one or more of such matrices and a device suitable to receive such a matrix provided with a milk application window and a read-out window has been described as well. Finally a kit-of-parts comprising such a diagnostic kit and one or more feeding doses of 2'fucosyl-glycans hasbeen disclosed.

The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.

The invention discloses an active composition containing copper peptide and a cosmetic or skin care product. The active composition containing copper peptide is prepared from the following components in percentage by weight: 0.001-2 percent of copper peptide, 1-5 percent of vitamin E, 0.1-10 percent of chitin oligosaccharide, 0.1-2 percent of 4-MSK, 0.1-5 percent of algal polysaccharides, 6-30 percent of emulsifier, 0-10 percent of co-emulsifier, 0.1-0.8 percent of stabilizer, 0-10 percent of excipient and the balance of water. The active composition and the cosmetic or skin care product have the effects of promoting cell reproduction, remarkably moisturizing and moistening, delaying senescence and the like.

Method for obtaining and expanding postembryonic hematopoietic stem cells from umbilical cord blood while avoiding unwanted differentiation. Initial cells from umbilical cord blood are proliferated and multiplied ex vivo in a stroma-free medium and in the presence of a regio-modified glycan or glycosaminoglycan. The regio-modified glycan or glycosaminoglycan, e.g. a heparin derivative, is N-desulfated, and N-reacetylated or N-reacylated, in essence, on C2 atoms. The heparin derivative advantageously comprises less than 5 percent of C3-O-sulfate, at least 60 percent C2-O-sulfate, and it is preferably added in a quantity of 15 to 50 mg / L to the medium in order to stop an unwanted differentiation. The stem cells generated in this manner can differentiate, after expansion, into myeloma cells and lymphatic cells, and they can be used as an immunotherapeutic agent against many diseases.

The present invention relates recombinant human α1-antitrypsin (rhAAT) comprising N-linked glycans, wherein at least 10% of said N-linked glycans are tetra-antennary glycans; and the degree of capping with sialic acid on said N-linked glycans (Z / A) is at least 50%. The invention further relates to rhAAT for use as a medicament, in particular for use in the prevention and / or treatment of a disease associated with AAT deficiency, and / or a disease involving neutrophil-mediated tissue damage.

The invention discloses a method for preparing gentio-oligosaccharide by using immobilized beta-glucosidase. The method for preparing the gentio-oligosaccharide by using the immobilized beta-glucosidase comprises the following steps of: 1) preparing beta-glucosidase through solid-state fermentation of Aspergillus niger; 2) immobilizing the beta-glucosidase by a crosslinking-embedding method; and 3) producing the gentio-oligosaccharide by transforming glucose by using the immobilized beta-glucosidase. The recovery rate of enzyme activity of an immobilized enzyme prepared by the method is up to 60 percent, and the conversion rate of a substrate, namely the glucose converted by the immobilized enzyme is 45 percent; and the stability and pH tolerance of the immobilized enzyme are remarkably improved, the mechanical strength is high, the immobilized enzyme can be continuously and repeatedly used for 4 to 6 bathes, and the enzyme activity is kept unchanged. The utilization rate of the gentio-oligosaccharide produced by an enzyme method is improved, the production cost and difficulty in separation and purification of the gentio-oligosaccharide are reduced, and the method is suitable for large-scale continuous production and has a great significance for improving the technical level of the production of the gentio-oligosaccharide in China.